Anthropic’s aggressive push toward a blockbuster IPO, with confidential S-1 filings and targeted timelines potentially after the November 2026 midterms, underpins the 97% market-implied odds against acquisition before 2027. Explosive revenue growth—annualized run rate surpassing $65 billion by July 2026 after reaching roughly $9 billion at end-2025—combined with a $65 billion Series H round at $965 billion valuation in May, has cemented its status as a standalone leader developing Claude models and pursuing internal initiatives like a new biology lab. Recent decisions to walk away from large acquisition talks further signal independence. While CEO Dario Amodei’s safety-focused calls for slower capability releases or regulatory shifts could theoretically prompt strategic consolidation, the company’s capital access, enterprise traction, and public-market momentum make a near-term takeover highly improbable.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoSí
3% probabilidad
$29,969 Vol.
$29,969 Vol.
31 dic 2026
Sí
3% probabilidad
$29,969 Vol.
$29,969 Vol.
31 dic 2026
This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.Anthropic’s aggressive push toward a blockbuster IPO, with confidential S-1 filings and targeted timelines potentially after the November 2026 midterms, underpins the 97% market-implied odds against acquisition before 2027. Explosive revenue growth—annualized run rate surpassing $65 billion by July 2026 after reaching roughly $9 billion at end-2025—combined with a $65 billion Series H round at $965 billion valuation in May, has cemented its status as a standalone leader developing Claude models and pursuing internal initiatives like a new biology lab. Recent decisions to walk away from large acquisition talks further signal independence. While CEO Dario Amodei’s safety-focused calls for slower capability releases or regulatory shifts could theoretically prompt strategic consolidation, the company’s capital access, enterprise traction, and public-market momentum make a near-term takeover highly improbable.
This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Mercado abierto: Nov 12, 2025, 5:14 PM ET
Volumen
$29,969Fecha de finalización
1 ene 2027Mercado abierto
Nov 12, 2025, 5:14 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.Anthropic’s aggressive push toward a blockbuster IPO, with confidential S-1 filings and targeted timelines potentially after the November 2026 midterms, underpins the 97% market-implied odds against acquisition before 2027. Explosive revenue growth—annualized run rate surpassing $65 billion by July 2026 after reaching roughly $9 billion at end-2025—combined with a $65 billion Series H round at $965 billion valuation in May, has cemented its status as a standalone leader developing Claude models and pursuing internal initiatives like a new biology lab. Recent decisions to walk away from large acquisition talks further signal independence. While CEO Dario Amodei’s safety-focused calls for slower capability releases or regulatory shifts could theoretically prompt strategic consolidation, the company’s capital access, enterprise traction, and public-market momentum make a near-term takeover highly improbable.
This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Volumen
$29,969Fecha de finalización
1 ene 2027Mercado abierto
Nov 12, 2025, 5:14 PM ETResolver
0x65070BE91...Anthropic’s aggressive push toward a blockbuster IPO, with confidential S-1 filings and targeted timelines potentially after the November 2026 midterms, underpins the 97% market-implied odds against acquisition before 2027. Explosive revenue growth—annualized run rate surpassing $65 billion by July 2026 after reaching roughly $9 billion at end-2025—combined with a $65 billion Series H round at $965 billion valuation in May, has cemented its status as a standalone leader developing Claude models and pursuing internal initiatives like a new biology lab. Recent decisions to walk away from large acquisition talks further signal independence. While CEO Dario Amodei’s safety-focused calls for slower capability releases or regulatory shifts could theoretically prompt strategic consolidation, the company’s capital access, enterprise traction, and public-market momentum make a near-term takeover highly improbable.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes